Tag: Mersana Therapeutics
Mersana and GSK Sign Option Agreement for the Co-Development and Commercialization...
Mersana Therapeutics and GSK have confirmed that the companies have entered into a global collaboration that provides GSK an exclusive option to co-develop and...
Mersana Therapeutics and Janssen Biotech Sign Agreement to Advance Novel Antibody-Drug...
Mersana Therapeutics has signed a research collaboration and license agreement with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to...
The 7th Annual World ADC Awards Winners – What’s Next
The World ADC Awards showcase companies, teams, and individuals in the industry, across 9 categories, at the forefront of cancer research today. Finalists and...
Mersana Presents Interim Phase 1 Data for XMT-1536 at the 2019...
Mersana Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates or ADCs targeting cancers in areas of high...
Mersana Therapeutics Focuses its Resources on Advancing XMT-1536, its First-in-Class ADC...
Mersana Therapeutics, a clinical-stage biopharmaceutical company developing a pipeline of antibody-drug conjugates or ADCs designed to target cancers in areas of high unmet need,...
Preclinical Data Supports the Development of XMT-1536 in a Broad Population...
Update data from preclinical studies with XMT-1536, an antibody-drug conjugates or ADC being developed by Mersana Therapeutics targeting NaPi2b, were presented in a poster...
AACR 2017: New Preclinical Data to be Presented on Mersana’s XMT-1522
Mersana Therapeutics earlier today announced that it will present data on its lead preclinical immunoconjugate, XMT-1522, at the American Association of Cancer Research (AACR)...
Mersana’s XMT-1536 Demonstrates Anti-tumor Activity in Lung Cancer Patient-Derived Xenograft Studies
Encouraging data from preclinical studies presented at the 2016 IASLC 17th World Conference on Lung Cancer, in Vienna, Austria, suggests that Mersana Therapeutics' immunoconjugate XMT-1536...
U.S. FDA Accepts Investigational New Drug Application for Mersana’s Lead Antibody-Drug...
The U.S. Food and Drug Administration (FDA) cleared Mersana Therapeutics’ Investigational New Drug (IND) application to begin Phase I clinical trials for its lead...
Best ADC Platform Technology Awarded to Mersana Therapeutics
This week, during the 7th World ADC Conference in San Diengo, Mersana Therapeutics, a biotechnology company focused on discovering and developing a pipeline of...
